Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03697408 · ClinicalTrials.gov registry record · Phase 1
Itacitinib + Everolimus in Hodgkin Lymphoma
A Phase 1 study of Classical Hodgkin Lymphoma, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT03697408 is a Phase 1 study of Classical Hodgkin Lymphoma that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 23 participants, below the 77-participant average among 8 other Classical Hodgkin Lymphoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03697408, a Phase 1 study of Classical Hodgkin Lymphoma, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Itacitinib
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-02-11 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03697408
The ClinicalTrials.gov registry entry for NCT03697408 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 77-participant average among 8 other Classical Hodgkin Lymphoma trials with a reported enrollment target (70% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Classical Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.
NCT03697408 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03697408 about?
NCT03697408 is a clinical study titled "Itacitinib + Everolimus in Hodgkin Lymphoma". This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).
What is the current status of trial NCT03697408?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2019-02-11. Estimated completion is 2027-06.
What conditions does trial NCT03697408 study?
This clinical trial studies the following conditions: Classical Hodgkin Lymphoma.
What interventions are being tested in trial NCT03697408?
The interventions under investigation include: Everolimus (DRUG), Itacitinib (DRUG).
Who is sponsoring clinical trial NCT03697408?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03697408 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Classical Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
RECRUITING · Phase 1
-
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
RECRUITING · Phase 1
-
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Phase Ib of L-NMMA and Pembrolizumab
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.